Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Bell

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Molecular Therapy Oncolytics|December 3, 2016
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodiesLaura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, et al.
EMBO Molecular Medicine|July 13, 2010
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virusFrederik C Roos, Andrew M Roberts, Irene I L Hwang, et al.
Oncoimmunology|June 15, 2018
Transforming the prostatic tumor microenvironment with oncolytic virotherapyMatthew J Atherton, Kyle B Stephenson, Fanny Tzelepis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2014
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseJiqing Zhang, Lee-Hwa Tai, Carolina S Ilkow, et al.
The Lancet. Oncology|May 23, 2008
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialByeong-Ho Park, Taeho Hwang, Ta-Chiang Liu, et al.
The Journal of Biological Chemistry|April 26, 2023
Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral developmentStephen Boulton, Mathieu J F Crupi, Siddharth Singh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
The Journal of Clinical Investigation|September 11, 2018
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockadeJoy Hsu, Jonathan J Hodgins, Malvika Marathe, et al.
International Journal of Molecular Sciences|March 6, 2021
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD InteractionEmily E F Brown, Reza Rezaei, Taylor R Jamieson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Molecular Therapy Oncolytics|December 3, 2016
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodiesLaura Evgin, Carolina S Ilkow, Marie-Claude Bourgeois-Daigneault, et al.
EMBO Molecular Medicine|July 13, 2010
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virusFrederik C Roos, Andrew M Roberts, Irene I L Hwang, et al.
Oncoimmunology|June 15, 2018
Transforming the prostatic tumor microenvironment with oncolytic virotherapyMatthew J Atherton, Kyle B Stephenson, Fanny Tzelepis, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2014
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseJiqing Zhang, Lee-Hwa Tai, Carolina S Ilkow, et al.
The Lancet. Oncology|May 23, 2008
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialByeong-Ho Park, Taeho Hwang, Ta-Chiang Liu, et al.
The Journal of Biological Chemistry|April 26, 2023
Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral developmentStephen Boulton, Mathieu J F Crupi, Siddharth Singh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
The Journal of Clinical Investigation|September 11, 2018
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockadeJoy Hsu, Jonathan J Hodgins, Malvika Marathe, et al.
International Journal of Molecular Sciences|March 6, 2021
Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD InteractionEmily E F Brown, Reza Rezaei, Taylor R Jamieson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Pageof 20